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PIPELINE TRxENDS
Non-Specialty Specialty
December 2016
Drug Name: Cannabidiol
Manufacturer: GW Pharmaceuticals
Indication: Dravet syndrome, LGS 
Formulation: Oral liquid
Phase III
Drug Name:  Abaloparatide
Manufacturer: Radius Health
Indication: Osteoporosis
Formulation: Subcutaneous injection
Epidiolex® (cannabidiol) is a liquid formulation 
of pure plant-derived cannabidiol. Cannabidiol is 
currently being investigated for the treatment of 
multiple pediatric epilepsy disorders, including 
Dravet syndrome and Lennox-Gastaut syndrome 
(LGS).
In a randomized, placebo-controlled Phase 
III trial of patients with Dravet syndrome (N=120), 
cannabidiol was added to the current anti-epileptic 
drug (AED) regimen of patients who had previously 
tried an average of ≥4 AEDs. Treatment with 
cannabidiol resulted in a median reduction in 
monthly convulsive seizures of 39 percent compared 
to 13 percent with placebo after 14 weeks (P=0.01). 
In a randomized, placebo-controlled Phase III trial 
of patients with LGS who were uncontrolled on 
their current AED regimens (N=171), treatment 
with cannabidiol resulted in a median reduction in 
monthly drop seizures of 44 percent compared to 
22 percent with placebo after 14 weeks (P=0.0135). 
Additional Phase III trials of cannabidiol for both 
Dravet syndrome and LGS are currently underway.
Currently, there are no FDA-approved 
treatments for Dravet syndrome. The FDA has 
granted the Orphan Drug designation to cannabidiol 
for the treatment of Dravet syndrome, LGS, Tuberous 
Sclerosis Complex, and infantile spasms. In addition, 
the FDA granted the Fast Track designation to 
cannabidiol for the treatment of Dravet syndrome 
in June 2014. An NDA submission for cannabidiol is 
anticipated in the first half of 2017.
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Abaloparatide is an anabolic agent that 
selectively activates the parathyroid hormone 
type 1 receptor. Abaloparatide is currently being 
developed for the treatment of osteoporosis in 
postmenopausal women. 
The randomized, controlled, double-blind, 
international Phase III ACTIVE trial (N=2,463) 
compared abaloparatide 80 mcg daily to placebo 
or open-label teriparatide 20 mcg daily. There 
was a 0.6 percent incidence of new vertebral 
fractures at 18 months among patients treated with 
abaloparatide compared to 4.2 percent incidence 
among patients in the placebo group (RR 0.14, 95 
percent CI 0.05 to 0.39, P<0.001). There was a 2.7 
percent incidence of nonvertebral fractures at 18 
months among patients treated with abaloparatide 
compared to 4.7 percent incidence among patients 
in the placebo group (hazard ratio [HR] 0.57, 95 
percent CI 0.32 to 1.00, P=0.049). In addition, 
treatment with abaloparatide resulted in significant 
increases in bone mineral density compared to 
placebo and teriparatide at 6, 12, and 18 months 
(P<0.001). The incidence of hypercalcemia was 
lower in patients treated with abaloparatide 
compared to teriparatide (3.4  versus 6.4 percent, 
respectively, P=0.006).
If approved, abaloparatide may provide an 
efficacious treatment option for osteoporosis in 
postmenopausal women. A New Drug Application 
(NDA) for abaloparatide has been accepted for 
review by the FDA and a decision is expected by 
March 30, 2017.
NDA
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Promising New Agents
Non-Specialty Specialty
Drug Name: Dupilumab
Manufacturer: Regeneron, Sanofi
Indication: Atopic dermatitis
Formulation: Subcutaneous injection
NDA
Drug Name: Elagolix
Manufacturer: AbbVie, Neurocrine
Indication: Endometriosis          
Formulation: Oral tablet
Drug Name: Guselkumab
Manufacturer: Janssen
Indication: Plaque psoriasis
Formulation: Subcutaneous injection
BLA
Dupixent® (dupilumab) is a fully 
human monoclonal antibody that blocks 
the signaling of interleukin (IL)-4 and IL-
13, two cytokines that are integral to the 
type 2 immune response. Dupilumab is 
currently being studied for the treatment of 
moderate-to-severe atopic dermatitis (AD). 
Two identical Phase III studies, SOLO 
1 (N=671) and SOLO 2 (N=708), compared 
treatment with dupilumab 300 mg weekly 
or every other week to placebo in patients 
with moderate-to-severe AD who were 
inadequate responders to or ineligible for 
topical treatment. Compared to placebo, 
treatment with either dupilumab regimen 
resulted in significant improvements in 
the primary endpoint, defined as a score 
of 0 or 1 (clear or almost clear) on the 
Investigator’s Global Assessment (IGA) and 
a reduction from baseline of ≥2 points in 
the IGA score from baseline to week 16 in 
both trials (P<0.001 for both comparisons). 
The most common adverse events were 
exacerbations of AD, injection-site 
reactions, and nasopharyngitis.   
If approved, dupilumab may offer 
an alternative for patients with AD who 
are uncontrolled on topical treatment, 
and would be the first targeted therapy 
available for the treatment of AD. 
Dupilumab is also being studied for the 
treatment of asthma, nasal polyposis, 
and eosinophilic esophagitis. Dupilumab 
was granted the Breakthrough Therapy 
designation and Priority Review status 
by the FDA, with a decision expected by 
March 29, 2017.
Guselkumab is a fully humanized 
anti-IL-23 monoclonal antibody with anti-
inflammatory properties. This agent is 
currently in development for the treatment 
of moderate-to-severe plaque psoriasis. 
The Phase II X-PLORE trial (N=293) 
compared guselkumab to placebo and 
adalimumab in adults with moderate-
to-severe plaque psoriasis. A greater 
proportion of patients treated with 
guselkumab achieved a Physician’s Global 
Assessment score of 0 or 1 at 16 weeks 
compared to adalimumab (79, 86, and 83 
percent for guselkumab 50 mg, 100 mg, 
and 200 mg, respectively, compared to 
58 percent for adalimumab, P<0.05 for all 
comparisons). 
The Phase III VOYAGE 1 trial (N=837) 
compared guselkumab to placebo and 
adalimumab in adults with moderate-
to-severe plaque psoriasis. Treatment 
with guselkumab resulted in significant 
improvements in the proportion of patients 
achieving IGA scores of 0 or 1 compared 
to adalimumab (85.1 versus 65.9 percent, 
respectively) and in the proportion 
of patients with at least a 90 percent 
improvement in the Psoriasis Area and 
Severity Index (PASI 90) at 16 weeks (73.3 
versus 49.7 percent, respectively, P<0.001 
for both). The difference between groups 
in the proportion of patients achieving PASI 
90 was similar at 24 weeks (80.2 versus 53.0 
percent, respectively, P<0.001).
If approved, guselkumab would be 
the first anti-IL-23 monocloncal antibody 
indicated for the treatment of moderate-to-
severe plaque psoriasis. A Biologics License 
Application (BLA) was submitted to the FDA 
in November 2016.
Elagolix is an orally-administered 
gonadotropin-releasing hormone (GnRH) 
antagonist that blocks GnRH signaling by 
binding to GnRH receptors in the pituitary 
gland. It is currently being investigated for 
the treatment of endometriosis and uterine 
fibroids.
The safety and efficacy of elagolix were 
evaluated in two randomized, double-blind 
Phase III trials which compared elagolix 
150 mg once daily or 200 mg twice daily 
to placebo in premenopausal women 
with moderate-to-severe endometriosis-
associated pain. The co-primary endpoints 
of dysmenorrhea and non-menstrual 
pelvic pain (NMPP), as measured by the 
Daily Assessment of Endometriosis Pain 
scale, were evaluated in both trials 
at months three and six. In the Violet 
PETAL study (N=872), 46 and 76 percent 
of patients treated with elagolix 150 mg 
and 200 mg, respectively, were classified 
as dysmenorrhea responders at three 
months compared to 20 percent of patients 
receiving placebo. In addition, 50 and 55 
percent of patients treated with elagolix 
150 mg and 200 mg, respectively, were 
classified as NMPP responders at three 
months, compared to 36 percent of patients 
receiving placebo. The results of the 
Solstice study (N=815) were similar, with 
both elagolix groups achieving the co-
primary endpoints at six months. 
If approved, elagolix would be the first 
GnRH antagonist approved for the treatment 
of endometriosis. An NDA submission is 
planned for 2017.
BL
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Drug Name: Solithromycin
Manufacturer: Cempra
Indication: CABP
Formulation: IV/oral
NDA
Drug Name: Sirukumab
Manufacturer: GSK, Janssen
Indication: Rheumatoid arthritis
Formulation: Subcutaneous injection
Drug Name: Midostaurin
Manufacturer: Novartis
Indication: AML, SM
Formulation: Oral capsule
NDA
SolitheraTM (solithromycin) is a novel 
fourth-generation macrolide and the first 
fluoroketolide. This agent is currently being 
studied for the treatment of community-
acquired bacterial pneumonia (CABP).
In the SOLITAIRE-ORAL trial (N=860), 
adults with confirmed pneumonia were 
randomized to receive oral solithromycin 
800 mg on day one, followed by 400 mg on 
days two through five and placebo on days 
six through seven, or oral moxifloxacin 400 
mg on days one through seven. The primary 
endpoint of early clinical response (ECR) 
was defined as an improvement in ≥2 of 
4 symptoms (cough, chest pain, sputum 
production, dyspnea) and no worsening 
in any symptom at 72 hours after the first 
dose. Treatment with solithromycin was 
non-inferior to moxifloxacin, with 78.2 
and 77.9 percent of patients, respectively, 
achieving an ECR (treatment difference 
0.29, 95 percent CI -5.5 to 6.1). 
In the SOLITAIRE-IV trial (N=863), adults 
with CABP were randomized to receive 
intravenous (IV)-to-oral solithromycin or 
moxifloxacin for seven once-daily doses. 
The primary endpoint of ECR was achieved 
by 79.3 and 79.7 percent of patients treated 
with solithromycin and moxifloxacin, 
respectively (treatment difference -0.46, 95 
percent CI -6.1 to 5.2). 
Solithromycin has activity against most 
macrolide-resistant strains of bacteria 
and may provide a potent macrolide 
monotherapy option for CABP. On Nov. 4, 
2016, an FDA advisory committee voted 
7 to 6 that the efficacy of solithromycin 
outweighs the risks. FDA decisions for the 
oral and IV formulations are expected by 
Dec. 27 and 28, 2016, respectively.
Midostaurin is a multi-targeted kinase 
inhibitor that targets both wild-type KIT 
and D816V-mutated KIT.  Midostaurin is 
currently being studied for the treatment of 
patients with acute myeloid leukemia (AML) 
with an FMS-like tyrosine kinase-3 (FLT3) 
mutation, as well as patients with advanced 
systemic mastocytosis (SM).
In the randomized, placebo-controlled 
Phase III RATIFY trial (N=717), treatment with 
midostaurin, in combination with standard 
induction and consolidation chemotherapy, 
was compared to chemotherapy alone for 
the treatment of newly-diagnosed FLT3-
mutated AML in patients ages 18 to 59.  
Treatment with midostaurin resulted in a 23 
percent improvement in overall survival (OS) 
compared to chemotherapy alone (HR 0.77, 
P=0.0074). The median OS with midostaurin 
was 74.7 months compared to 25.6 months 
with chemotherapy alone (95 percent CI 31.7 
to not attained and 95 percent CI 18.6 to 
42.9, respectively). In an open-label Phase II 
study of patients with SM (N=89), patients 
treated with midostaurin had an overall 
response rate of 60 percent (95 percent 
CI 49 to 70, P<0.001), a median OS of 28.7 
months, and a median progression-free 
survival (PFS) of 14.1 months.
If approved, midostaurin would be 
the first targeted therapy for AML, with 
significant improvements in OS compared 
to chemotherapy alone. The FDA granted 
the Breakthrough Therapy designation to 
midostaurin on Feb. 19, 2016. Following 
a priority review, an FDA decision is 
expected in the first half of 2017.
Sirukumab is a human anti-IL-6 
monoclonal antibody being studied for 
the treatment of moderate-to-severely 
active rheumatoid arthritis (RA) in adults. 
By binding to IL-6, sirukumab inhibits 
inflammation in RA. 
The Phase III SIRROUND-H study (N=559) 
compared treatment with sirukumab 50 
mg every four weeks or 100 mg every 
two weeks to adalimumab 40 mg every 
two weeks for 52 weeks, all given as 
monotherapy in patients who were ineligible 
for methotrexate due to a history of an 
adverse reaction, inadequate response, 
or contraindication. Co-primary endpoints 
included change from baseline in Disease 
Activity Index Score 28 using erythrocyte 
sedimentation rate [DAS28 (ESR)] and 
American College of Rheumatology 50 
(ACR50) response, both assessed at 24 
weeks. Improvements in DAS28 (ESR) were 
greater in the sirukumab 100 mg and 50 
mg groups compared to the adalimumab 
group (-2.96, -2.58 versus -2.19, respectively, 
P<0.001 and P=0.013, respectively). The 
ACR50 response was similar between the 
sirukumab and adalimumab groups. 
The SIRROUND clinical program includes 
five studies evaluating sirukumab in more 
than 3,000 patients as monotherapy or 
combined with conventional disease-
modifying antirheumatic drugs (DMARDs). 
If approved, sirukumab may offer an 
efficacious alternative for patients with RA 
who are ineligible for or who have failed 
DMARDs. A BLA was submitted for FDA 
review in September 2016.
BLA
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CabometyxTM (cabozantinib)
The Phase II randomized, active-controlled CABOSUN 
trial (N=157) compared treatment with cabozantinib 
60 mg once daily to sunitinib 50 mg once daily, given 
in cycles of four weeks on and two weeks off, in 
patients with previously untreated advanced renal cell 
carcinoma. Treatment with cabozantinib resulted in a 
31 percent reduction in the rate of disease progression 
or death at a median follow-up of 20.8 months (HR 
0.69, 95 percent CI 0.48 to 0.99, P=0.012), as well as a 
greater median PFS (8.2 versus 5.6 months) and median 
OS (30.3 versus 21.8 months) compared to sunitinib. An 
NDA submission is planned based on these findings.
Xeljanz® (tofacitinib)  
The Phase III randomized, double-blind, parallel group, 
placebo-controlled OCTAVE Sustain trial (N=593) 
compared maintenance treatment with tofacitinib 5 
mg and 10 mg twice daily to placebo in patients with 
moderate-to-severely active ulcerative colitis who had 
previously achieved a response in the OCTAVE Induction 
1 or 2 trials, which evaluated the efficacy of tofacitinib 
in inducing remission after eight weeks. At week 52, 
the proportion of patients who achieved remission 
was significantly greater in both tofacitinib treatment 
groups compared to placebo. The long-term OCTAVE 
Open extension trial is currently ongoing.
•  Azilect® (rasagiline mesylate)
     2/2017       
      
•  Tamiflu®  (oseltamivir capsules) 
     2/2017
•  MinastrinTM 24 Fe (ethinyl estradiol/ 
 norethindrone acetate/ferrous  
 fumarate) 
     3/2017
   
•  Pristiq® (desvenlafaxine succinate  
 extended-release tablet)
     3/2017 
•  Vytorin® (ezetimibe/simvastatin)
     4/2017    
 
•  Zetia® (ezetimibe) 
     4/2017
     
•  Strattera® (atomoxetine) 
     5/2017
•  Adcirca® (tadalafil)
     11/2017 
AndexXaTM (andexanet alfa)
On Aug. 17, 2016, Portola Pharmaceuticals Inc. 
announced that the FDA issued a Complete 
Response Letter (CRL) regarding the BLA for 
andexanet alfa, to which the Breakthrough 
Therapy designation had previously been 
granted for the reversal of direct or indirect 
Factor Xa inhibition in the setting of life-
threatening or uncontrolled bleeding. The 
FDA requested additional information related 
to product manufacturing, as well as data 
to support the inclusion of edoxaban and 
enoxaparin in the product label. Currently, 
there is no FDA-approved antidote for Factor Xa 
inhibitor therapy.
Deutetrabenazine (SD-809)
On Oct. 20, 2016, Teva announced that the FDA 
had accepted for review the NDA resubmission 
for deutetrabenazine, an oral small molecule 
inhibitor of vesicular monoamine 2 transporter 
(VMAT2) that is being studied for the treatment 
of chorea associated with Huntington disease. 
This resubmission follows the CRL issued by the 
FDA in May 2016. In the CRL, the FDA did not 
request additional clinical trials, but requested 
that the manufacturer examine blood levels 
of certain metabolites that have been 
observed in individuals taking tetrabenazine or 
deutetrabenazine. An FDA decision is expected 
by April 3, 2017.
ParsabivTM (etelcalcetide)
On Aug. 24, 2016, Amgen announced that the 
FDA issued a CRL declining approval of the 
NDA for etelcalcetide in its current form. 
Etelcalcetide is a novel, IV calcimimetic agent 
in development for the treatment of secondary 
hyperparathyroidism in adult patients with 
chronic kidney disease who are receiving 
hemodialysis. Amgen is currently reviewing 
the CRL decision and anticipates a post-action 
meeting with the FDA later this year to discuss 
further. Although the details of the CRL were 
not disclosed, Amgen has indicated that it does 
not impact their regulatory submissions in other 
regions.
*Dates are estimates, current as of 12/2/16, and are subject to change due to any patent litigation or additional patents.
•  Prezista® (darunavir tablet)
     11/2017 
•  Reyataz® (atazanavir) 
     12/2017
                      
•  Sustiva® (efavirenz) 
     12/2017
  
 • Truvada® (emtricitabine/  
 tenofovir disoproxil fumarate) 
     12/2017  
• Viagra®  (sildenafil)
  12/2017
 
• Viread® (tenofovir disoproxil  
 fumarate tablet)
  12/2017                                     
 
• Treximet® (sumatriptan/  
 naproxen)
  2/2018
•  Solodyn® (minocycline 
 extended-release tablet)
     2/2018 
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Note: All agents are administered orally unless otherwise indicated. 
*Designates specialty drug.
IBS-C, CIC
Relapsing-remitting, 
primary progressive MS
Genentech
Table Abbreviations: ALK=anaplastic lymphoma kinase, ALS=amyotrophic 
lateral sclerosis, CIC=chronic idiopathic constipation, CINV=chemotherapy-
induced nausea and vomiting, CNCP=chronic non-cancer pain, HR=hormone 
receptor, HER2=human epidermal growth factor receptor 2, IBS-C=irritable 
bowel syndrome with constipation, ICV=intracerebroventricular, 
MS=multiple sclerosis, NSCLC=non-small cell lung cancer, 
PDUFA=Prescription Drug User Fee Act, SC=subcutaneous
Ocrevus®                    
(ocrelizumab)* (IV)
PDUFA date 12/28/2016
Atopic dermatitis
Rolapitant (IV) CINV prophylaxis
Plaque psoriasis
Deflazacort PDUFA date 02/2017
BrineuraTM                    
(cerliponase alfa)* (ICV)
BioMarin 
Pharmaceutical
CLN2 disease
Brigatinib*
Ariad 
Pharmaceuticals
Metastatic              
ALK+ NSCLC
RadicavaTM                 
(edaravone)* (IV)
ALS PDUFA date 06/16/2017
Telotristat etiprate*
Lexicon 
Pharmaceuticals
PDUFA date 02/28/2017
Ribociclib*
Impetigo PDUFA date 06/22/2017
Clovis Oncology
Advanced 
BRCA-mutated ovarian 
cancer
PDUFA date 02/23/2017
PDUFA date 01/29/2017
PDUFA date 01/07/2017
PDUFA date 01/11/2017
Carcinoid syndrome
Rucaparib*
Crisaborole (topical)
Synergy 
Pharmaceuticals
PDUFA date 02/16/2017
Naldemedine Shionogi PDUFA date 03/23/2017
PDUFA date 04/27/2017
PDUFA date 04/29/2017
HR+/HER2- advanced 
breast cancer
NDA accepted 11/2016
INGREZZATM                  
(valbenazine)
Tardive dyskinesia PDUFA date 04/11/2017
Ozenoxacin (topical)
Coherus Biosciences
Prevention of 
chemotherapy-induced 
febrile neutropenia
PDUFA date 06/09/2017
CHS-1701                    
(pegfilgrastim biosimilar)* 
(SC)
Medimetriks
Pharmaceuticals
Siliq                     
(brodalumab)* (SC)
Plecanatide
Anacor 
Pharmaceuticals
Valeant 
Pharmaceuticals
Tesaro
Marathon 
Pharmaceuticals
Duchenne muscular 
dystrophy
Opioid-induced 
constipation in CNCP
Neurocrine 
Biosciences
Novartis
Mitsubishi Tanabe 
Pharma Corporation
Phase I:   36.6%
Phase II:  44.6%
Phase III: 18.8%
Agents in Clinical Development
Leading Indications with Agents in 
Late-Stage Development
1. Breast cancer
2. Non-small cell lung cancer
3. Colorectal cancer
4. Pancreatic cancer
5. Type 2 diabetes mellitus
6. Rheumatoid arthritis
7. Ovarian cancer
8. Alzheimer’s disease
9. Prostate cancer
10. Melanoma
Phase III
Phas
e I
Ph
as
e 
II
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